Search results for "arki"

showing 10 items of 1015 documents

VALIDATING SCREENING INSTRUMENTS FOR NEUROEPIDEMIOLOGIC SURVEYS - EXPERIENCE IN SICILY

1992

In a hospital setting in Sicily, we assessed a screening instrument developed for a prevalence survey of parkinsonism, peripheral neuropathies, stroke, and epilepsy. The subjects consisted of (1) hospital patients with any of the above-mentioned diseases, to investigate sensitivity; and (2) hospital visitors free of all these diseases, to investigate specificity. The standard for comparison was a clinical evaluation based on specified criteria. Trained interviewers administered the screening instrument, asking subjects to answer symptom questions and to perform simple physical tasks. For the questions and tasks together, the sensitivity estimates were 100% for parkinsonism (n = 21), 96% for…

medicine.medical_specialtyEpidemiologybusiness.industryParkinsonismPublic healthTest validityPrevalence surveymedicine.diseaseEpilepsyEpidemiologymedicinePhysical therapybusinessStrokeScreening instrument
researchProduct

Anderson‐Fabry Disease: A Rare Cause of Levodopa‐Responsive Early‐Onset Parkinsonism

2021

NA

medicine.medical_specialtyLevodopabusiness.industryEarly onset parkinsonismGastroenterologyAnderson-Fabry DiseaseNeurologyInternal medicinemedicineAnderson-Fabry disease early onset parkinsonism levodopa response lysosomal storage diseasesSettore MED/26 - NeurologiaNeurology (clinical)businessCase Reports and Commentariesmedicine.drugMovement Disorders Clinical Practice
researchProduct

2019

OBJECTIVE With a combination of different sympathetic tests, we aimed to elucidate whether impairment of sympathetic function in Parkinson's disease (PD) is the consequence of a central or peripheral efferent dysfunction. METHODS Thirty-five patients with early-to-intermediate PD (median age: 63 years; IQR: 57-67 years; disease duration 1-9 years, 15 women) and 20 age- and sex-matched healthy controls (median age: 64.5 years; IQR: 58-68 years; 10 women) were recruited. Autonomic testing was performed in two subgroups and included the assessment of resting cardiovascular parameters, postprandial hypotension (PPH), orthostatic hypotension (OH), and vasoconstriction induced by intradermal micr…

medicine.medical_specialtyMicrodialysisParkinson's diseasebusiness.industry05 social sciencesMicroneurographymedicine.disease050105 experimental psychology03 medical and health sciencesBehavioral NeuroscienceOrthostatic vital signsNorepinephrine0302 clinical medicineBlood pressureInternal medicinemedicineCardiology0501 psychology and cognitive sciencesmedicine.symptomPure autonomic failurebusiness030217 neurology & neurosurgeryVasoconstrictionmedicine.drugBrain and Behavior
researchProduct

PGC-1α: a master gene that is hard to master

2012

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that favorably affects mitochondrial function. This concept is supported by an increasing amount of data including studies in PGC-1α gene-deleted mice, suggesting that PGC-1α is a rescue factor capable of boosting cell metabolism and promoting cell survival. However, this view has now been called into question by a recent study showing that adeno-associated virus-mediated PGC-1α overexpression causes overt cell degeneration in dopaminergic neurons. How is this to be understood, and can these seemingly conflicting findings tell us something about the role of PGC-1α in cell stress and in cont…

medicine.medical_specialtyModels NeurologicalSettore BIO/11 - Biologia MolecolareRNA-binding proteinBiologyMitochondrionSettore BIO/09 - FisiologiaMiceCellular and Molecular NeuroscienceHeat shock proteinInternal medicinemedicineAnimalsHomeostasisHumansReceptorMolecular BiologyTranscription factorHeat-Shock ProteinsMice KnockoutPharmacologyPGC-1α Mitochondria Dopaminergic neurons Transgenic animal Adenovirus Parkinson’s diseaseDopaminergic NeuronsDopaminergicRNA-Binding ProteinsParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaEndocrinologyCell metabolismNerve DegenerationTrans-ActivatorsMolecular MedicineNeuroscienceHomeostasisTranscription FactorsCellular and Molecular Life Sciences
researchProduct

Depression and Movement Disorders

2012

medicine.medical_specialtyMovement disordersParkinson's diseaseHuntington's diseasebusiness.industrymedicineAnxietymedicine.symptommedicine.diseasebusinessNeuropsychiatryPsychiatryDepression (differential diagnoses)Depression in Neurologic Disorders: Diagnosis and Management
researchProduct

Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia.

2020

BACKGROUND: Little information is available on the official postgraduate and subspecialty training programs in movement disorders (MD) in Europe and North Africa.OBJECTIVE: To survey the accessible MD clinical training in these regions.METHODS: We designed a survey on clinical training in MD in different medical fields, at postgraduate and specialized levels. We assessed the characteristics of the participants and the facilities for MD care in their respective countries. We examined whether there are structured, or even accredited postgraduate, or subspecialty MD training programs in neurology, neurosurgery, internal medicine, geriatrics, neuroradiology, neuropediatrics, and general practic…

medicine.medical_specialtyMovement disordersTunisiaParkinson's diseaseeducationNorth africaCertificationSubspecialtyDIAGNOSIS3124 Neurology and psychiatryAccreditation03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinemedicineHumans030212 general & internal medicineCurriculumAccreditationGeriatricsMedical educationeducationMovement Disorders4. Education3112 Neurosciences3. Good healthEuropeNeurologyEducation Medical GraduateClinical trainingHealth Care SurveysSUBSPECIALIZATIONEgyptNeurology (clinical)Curriculummedicine.symptomPsychology030217 neurology & neurosurgeryJournal of Parkinson's disease
researchProduct

Acute reversible parkinsonism in a diabetic-uremic patient.

2005

Acute movement disorders with basal ganglia lesions have been recently described in diabetic-uremic patients of Asian descent. The process is often reversible, with a favourable clinical outcome. Metabolic (i.e. uremic toxins) and microangiopathic changes have been suggested to be involved in its pathophysiology, even though racial and/or genetic factors might play a role too. In this report, we present a Caucasian diabetic patient with a long-lasting mild uremia in which acute parkinsonism occurred after a steep and unexpected increase of the serum creatinine. The follow-up demonstrated a significant improvement of the neurological signs and symptoms, the creatinine level lowered close to …

medicine.medical_specialtyMovement disordersacute parkinsonismGastroenterologyWhite PeopleDiabetes Complicationschemistry.chemical_compoundParkinsonian DisordersDiabetes mellitusInternal medicinemedicineHumansAgedUremiaCreatininediabetes mellitubusiness.industryParkinsonismGeneral Medicinemedicine.diseasePathophysiologyUremiaSurgerychemistryCreatininebasal gangliaAcute DiseaseSurgeryFemaleNeurology (clinical)medicine.symptomDifferential diagnosisbusinessKidney diseaseClinical neurology and neurosurgery
researchProduct

Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown

2020

Objective: The effects of the COVID-19 lockdown on subjects with prodromal phases of dementia are unknown. The aim of this study was to evaluate the motor, cognitive, and behavioral changes during the COVID-19 lockdown in Italy in patients with Parkinson's disease (PD) with and without mild cognitive impairment (PD-MCI and PD-NC) and in patients with MCI not associated with PD (MCInoPD).Methods: A total of 34 patients with PD-NC, 31 PD-MCI, and 31 MCInoPD and their caregivers were interviewed 10 weeks after the COVID-19 lockdown in Italy, and changes in cognitive, behavioral, and motor symptoms were examined. Modified standardized scales, including the Neuropsychiatric Inventory (NPI) and t…

medicine.medical_specialtyMultivariate analysisActivities of daily livingParkinson's diseaselcsh:RC435-571behavioral symptomsParkinson's diseaseDiseasebehavioral symptoms caregiver burden cognitive impairment COVID-19 motor impairment Parkinson's disease quarantinemotor impairment03 medical and health sciences0302 clinical medicineRating scalelcsh:PsychiatryInternal medicinemental disordersmedicineDementiaOriginal Researchcognitive impairmentPsychiatrycaregiver burden030214 geriatricsbusiness.industryquarantineCOVID-19CognitionCaregiver burdenmedicine.diseasePsychiatry and Mental healthbusiness030217 neurology & neurosurgeryFrontiers in Psychiatry
researchProduct

Practical importance of neuroprotection in Parkinson's disease.

2003

Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeu…

medicine.medical_specialtyNeurologyParkinson's diseaseIndolesBioinformaticsNeuroprotectionAntiparkinson AgentsDegenerative diseaseSelegilineAmantadineMedicineHumansbusiness.industrySelegilineAmantadineParkinson Diseasemedicine.diseaseClinical trialRopiniroleNeuroprotective AgentsNeurologyDopamine AgonistsNeurology (clinical)businessNeurosciencemedicine.drugJournal of neurology
researchProduct

Common risk factors of three diseases.

1992

medicine.medical_specialtyNeurologybusiness.industryGeneral NeurosciencePublic healthAmyotrophic Lateral SclerosisMEDLINEParkinson DiseaseEnvironmental ExposureAlzheimer DiseaseRisk FactorsFamily medicineMedicineHumansNeurology (clinical)NeurosurgeryRisk factorbusinessNeuroradiologyItalian journal of neurological sciences
researchProduct